회사 개요
Zhengye Biotechnology Holding Limited is a specialized enterprise focused on the research, development, manufacturing, and commercialization of veterinary vaccines specifically for the livestock sector within China. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a reliance on regulatory approvals and scientific innovation to produce essential biological products for agriculture. The entity currently maintains a market capitalization of $45.28M and employs a workforce of 277 individuals to support its operational and research activities. The annual revenue generated over the trailing twelve months stands at $153.74M, indicating that while the company generates substantial top-line sales, its relatively small market cap suggests it is valued as a niche player rather than a dominant market leader in the broader biotechnology landscape.
재무 건전성
The financial statements reveal a Trailing Twelve Months revenue of $153.74M, yet the company recorded a net income loss of $-19,368,000 and an EBITDA of $-2,213,000 during the same period. The significant disparity between the $153.74M in revenue and the substantial net loss highlights a challenging cost structure where expenses, likely driven by R&D and production costs for veterinary vaccines, are currently outpacing gross profitability. Despite the operating losses, the company possesses $47.63M in cash reserves, resulting in a positive free cash flow of $24.23M, which provides a degree of financial flexibility to fund operations or R&D without immediate external financing. Profitability metrics are under pressure, evidenced by a gross margin of 37.4%, a negative operating margin of -46.3%, and a profit margin of -12.6%, all indicating that the company is not yet achieving operational breakeven. On the balance sheet, total debt of $85.76M exceeds the cash position of $47.63M, contributing to a debt-to-equity ratio of 23.49, which characterizes the capital structure as highly leveraged rather than conservative. Liquidity is maintained at a current ratio of 1.49, suggesting the company holds sufficient current assets to cover short-term obligations, although the high leverage remains a risk factor. Return on Equity stands at -6.4% and Return on Assets at -3.4%, metrics that collectively reveal that management has not yet generated positive returns on shareholder capital or invested assets.
밸류에이션 평가
Valuation multiples for the company are unavailable in traditional terms, as the P/E Ratio (TTM) and Forward P/E are both listed as N/A, reflecting the inability to value the stock based on current or future earnings due to the reported net losses. The absence of a positive P/E ratio implies that investors cannot rely on earnings-based valuation models and must instead look to asset-based metrics, such as the Price to Book ratio of 1.04, which indicates the stock trades at a value slightly above its book value per share. Alternative valuation metrics further illustrate the company's financial state, with a Price to Sales ratio of 0.29 and an EV/EBITDA of -67.59, suggesting the market is pricing the company based on its revenue generation potential and cash flow characteristics rather than profitability. The stock's price volatility is defined by a 52-Week High of $14.30 and a 52-Week Low of $0.68, indicating a wide trading range that suggests significant market uncertainty or speculative interest. Without a Beta value provided (listed as N/A), the specific sensitivity of the stock price to broader market movements cannot be quantified, but the wide range between the high and low implies substantial price fluctuation over the past year.
Growth & Income
Growth metrics show a Revenue Growth (YoY) of -34.4%, while Earnings Growth (YoY) is N/A, indicating that the company is currently experiencing a contraction in sales volume rather than expansion. The lack of earnings growth data combined with negative revenue growth suggests a challenging market environment or a decline in demand for specific veterinary vaccine lines within the Chinese livestock sector. The company does not pay a dividend, as indicated by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that instead of returning cash to shareholders, the company retains all earnings to potentially offset losses or fund future R&D initiatives. Consequently, the overall growth and income profile for Zhengye Biotechnology Holding Limited is characterized by negative revenue momentum and a complete absence of income generation through dividends or positive earnings growth.